Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ: EWTX )

27.88 -0.12 (-0.43%)
Streaming Delayed Price Updated: 3:40 PM EST, Jan 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
From Edgewise Therapeutics
Via Business Wire
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
Dow Eyes Worst Losing Streak Since 2018
The Nasdaq Composite is up triple digits midday, hitting fresh record highs as it looks to build off a fourth-straight weekly win. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
Edgewise Therapeutics reports promising Phase 2 results for sevasemten, showing reduced muscle damage and well-tolerated safety in Becker muscular dystrophy. 
Via Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
From Edgewise Therapeutics
Via Business Wire
MarketBeat Week in Review – 9/23 - 9/27
Stocks had a mostly bullish week as stimulus efforts in the U.S. and China enhanced risk-on sentiment, but next week's jobs report could spark a larger rally 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run? 
Via MarketBeat
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap stocks last week. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Crude Oil Gains Over 1%; Mobileye Global Shares Jump
Via Benzinga
Exposures Fossil Fuels
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Edgewise Therapeutics is rocketing higher on positive results for its HCM combating treatment and short-covering. Expect volatility in the weeks ahead. 
Via MarketBeat
Why Edgewise Therapeutics Stock Is Up 50% on Thursday
One of the biopharma company's heart drugs performs as well as initially hoped. 
Via The Motley Fool
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment
Edgewise Therapeutics announced topline data from Phase 1 and Phase 2 trials of EDG-7500 for obstructive hypertrophic cardiomyopathy, showing the drug was well tolerated with reductions in LVOT... 
Via Benzinga
Darden Restaurants Posts Q1 Results, Joins Tesla, Nvidia, XPeng And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics. 
Via Investor's Business Daily
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
From Edgewise Therapeutics
Via Business Wire
EWTX Stock Earnings: Edgewise Therapeutics Beats EPS for Q2 2024
EWTX stock results show that Edgewise Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
7 Small-Cap Stocks to Buy for Large-Scale Gains
Although small-cap stocks are incredibly risky, their underappreciated nature potentially gives them a high performance ceiling. 
Via InvestorPlace
Stock Market News For July 23: Quick Takes On GE Aerospace, Boeing, Biotechs
What sectors outperformed after Trump won the 2016 election, and which outperformed during his term? 
Via Investor's Business Daily
Topics Government
Exposures Political
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.